## MAKING A DIFFERENCE - THE MATRIX METHAMPHETAMINE PROGRAM - CLIENTS RECOVERY STORIES

Authors: QUENTIN C. BLACK, NICOLE BOWERING, JANE OAKES & ELLY GANNON

<sup>1</sup>University of NSW, Sydney, Australia, <sup>2</sup> Australasian Professional Society on Alcohol and other Drugs, Sydney, Australia, <sup>3</sup>The Kirby Institute, Melbourne, Australia

Presenter's email: quentinblack@bigpond.com

Introduction / Issues <u>OR</u> Introduction and Aims: The use of methamphetamine is widespread and contributed to a considerable number of deaths in Australia (Kaye et al.2008; Lee, & Rawson (2008) and poses a significant challenge for treatment providers. PsychMed has developed an Australian adaptation of the US Matrix program currently the gold standard therapeutic approach for methamphetamine dependence providing an evidence-based structured approach using high intensity therapy that leads to the success of the Matrix program (Black et al 2018). This qualitative study is part of a larger study.

**Aim:** This presentation provides examples of the experiences of participants with a history of Methamphetamine use who completed the Matrix program.

**Method / Approach OR Design and Methods:** Clients who have engaged the Matrix program provided case studies and artwork reflecting their progression from intake to treatment completion.

**Key Findings OR Results:** Clients developed specific skills that have enabled them to remain abstinent.

**Discussions and Conclusions:** These case studies demonstrate the efficacy of the Matrix program for the treatment of high-risk methamphetamine users.

- 1. Kaye, S., Darke, S., Duflou, J., & McKetin, R. (2008). Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction, 103(8), 1353-1360.
- Lee, N. K., & Rawson, R. A. (2008). A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and alcohol review, 27(3), 309-317

**Disclosure of Interest Statement:** WT has received funding from Metabolism Corp. No pharmaceutical grants were received in the development of this study.